Linagliptin cardiovascular safety profile appears superior to glimepiride

Article

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Related Videos
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Robert E. Oshel, PhD
Related Content
© 2023 MJH Life Sciences

All rights reserved.